

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings of claims, in the application:

**LISTING OF CLAIMS:**

1. (Currently amended) A method of treating a condition related to resistance to cell death, comprising administering to a patient a pharmaceutical composition comprising a ~~eupredoxin~~ an azurin, a mutant azurin or a truncated azurin, to promote cell death in a cell demonstrating resistance to cell death.
2. (Currently amended) The method of claim 1, wherein the ~~eupredoxin~~ azurin, mutant azurin or truncated azurin binds to tumor-suppressor protein p53.
3. (Canceled)
4. (Canceled)
5. (Currently amended) The method of claim [[4]] 1, wherein the ~~eupredoxin~~ azurin is an azurin comprising comprises the amino acid sequence of SEQ ID NO: 1, ~~a mutant azurin or a truneated azurin~~.
6. (Canceled)
7. (Currently amended) The method of claim [[4]] 1, wherein the mutant azurin comprises the amino acid sequence selected from the group consisting of SEQ ID NOS: 6, 7, 45, 46, 47, 48, 50, 51, 52, and 53.
- 8.-19. (Canceled)
20. (Previously presented) The method of claim 1 wherein the condition related to resistance to cell death is selected from the group consisting of human melanoma, leukemia, breast cancer, ovarian cancer, lung cancer, mesenchymal cancer, colon cancer and aerodigestive tract cancers.
21. (Canceled)